Teva (NYSE: TEVA) CAO converts 3,537 RSUs into ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.

The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.

Insider Trade Summary

3,537 shares exercised/converted

Mixed 2 txns

Insider Weiss Amir

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	3,537	$0.00	--
Exercise	Ordinary Shares	3,537	$0.00	--

Holdings After Transaction: Restricted Share Units — 10,613 shares (Direct); Ordinary Shares — 30,695 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiss Amir

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		3,537	A	(2)	30,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			3,537	(3)	(3)	Ordinary Shares(1)	3,537	$0	10,613	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 5, 2025, with 3,537 vested on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teva (TEVA) report for Amir Weiss?

Teva reported that Chief Accounting Officer Amir Weiss converted 3,537 restricted share units into 3,537 ordinary shares on March 5, 2026, at a zero exercise price. This reflects routine vesting of previously granted equity compensation, not an open-market stock purchase or sale.

When were the Teva (TEVA) restricted share units granted and how do they vest?

The restricted share units were granted on March 5, 2025. Vesting is scheduled as 3,537 units on March 5, 2026, 3,537 on March 5, 2027, 3,537 on March 5, 2028, and 3,539 on March 5, 2029, subject to continued service and plan conditions.

How many Teva (TEVA) ordinary shares does Amir Weiss hold after this transaction?

Following the March 5, 2026 conversion, Amir Weiss directly held 30,695 ordinary shares of Teva. This reflects the addition of 3,537 shares from vested restricted share units, as disclosed, and represents his updated direct share ownership position after the equity award vesting.

How many Teva (TEVA) restricted share units remain outstanding for Amir Weiss?

After the March 5, 2026 vesting event, Amir Weiss held 10,613 restricted share units. These units are scheduled to vest in future installments in 2027, 2028, and 2029, according to the award’s vesting schedule described in the disclosure footnotes.

Can Teva (TEVA) ordinary shares be held as American Depositary Shares (ADS)?

Yes. The disclosure states that Teva Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share. This allows investors to hold Teva equity through ADSs while maintaining a one-for-one relationship with underlying ordinary shares.

Is the Teva (TEVA) Form 4 transaction a market buy or sell?

No. The Form 4 characterizes the code M transaction as an exercise or conversion of a derivative security, meaning restricted share units vested into ordinary shares at no exercise price. It does not represent an open-market buy or sell of Teva stock.